172 related articles for article (PubMed ID: 28055201)
1. Tumor Microenvironment-Sensitive Liposomes Penetrate Tumor Tissue via Attenuated Interaction of the Extracellular Matrix and Tumor Cells and Accompanying Actin Depolymerization.
Suzuki S; Itakura S; Matsui R; Nakayama K; Nishi T; Nishimoto A; Hama S; Kogure K
Biomacromolecules; 2017 Feb; 18(2):535-543. PubMed ID: 28055201
[TBL] [Abstract][Full Text] [Related]
2. Growth of Metastatic Triple-Negative Breast Cancer Is Inhibited by Deep Tumor-Penetrating and Slow Tumor-Clearing Chemotherapy: The Case of Tumor-Adhering Liposomes with Interstitial Drug Release.
Stras S; Howe A; Prasad A; Salerno D; Bhatavdekar O; Sofou S
Mol Pharm; 2020 Jan; 17(1):118-131. PubMed ID: 31825626
[TBL] [Abstract][Full Text] [Related]
3. Effective cytoplasmic release of siRNA from liposomal carriers by controlling the electrostatic interaction of siRNA with a charge-invertible peptide, in response to cytoplasmic pH.
Itakura S; Hama S; Matsui R; Kogure K
Nanoscale; 2016 May; 8(20):10649-58. PubMed ID: 27145993
[TBL] [Abstract][Full Text] [Related]
4. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system.
Chen B; Dai W; Mei D; Liu T; Li S; He B; He B; Yuan L; Zhang H; Wang X; Zhang Q
J Control Release; 2016 Nov; 241():68-80. PubMed ID: 27641831
[TBL] [Abstract][Full Text] [Related]
5. Overcoming the polyethylene glycol dilemma via pathological environment-sensitive change of the surface property of nanoparticles for cellular entry.
Hama S; Itakura S; Nakai M; Nakayama K; Morimoto S; Suzuki S; Kogure K
J Control Release; 2015 May; 206():67-74. PubMed ID: 25770398
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
7. Leukocyte-Mimetic Liposomes Penetrate Into Tumor Spheroids and Suppress Spheroid Growth by Encapsulated Doxorubicin.
Fukuta T; Yoshimi S; Kogure K
J Pharm Sci; 2021 Apr; 110(4):1701-1709. PubMed ID: 33129835
[TBL] [Abstract][Full Text] [Related]
8. Delivering anti-cancer drugs with endosomal pH-sensitive anti-cancer liposomes.
Moku G; Gulla SK; Nimmu NV; Khalid S; Chaudhuri A
Biomater Sci; 2016 Apr; 4(4):627-38. PubMed ID: 26806172
[TBL] [Abstract][Full Text] [Related]
9. Liposomes as a Promising Ultrasound-Triggered Drug Delivery System in Cancer Treatment.
Salkho NM; Turki RZ; Guessoum O; Martins AM; Vitor RF; Husseini GA
Curr Mol Med; 2017; 17(10):668-688. PubMed ID: 29663885
[TBL] [Abstract][Full Text] [Related]
10. RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells.
Kang MH; Park MJ; Yoo HJ; hyuk KY; Lee SG; Kim SR; Yeom DW; Kang MJ; Choi YW
Eur J Pharm Biopharm; 2014 Aug; 87(3):489-99. PubMed ID: 24704199
[TBL] [Abstract][Full Text] [Related]
11. Multi-functional vesicles for cancer therapy: The ultimate magic bullet.
Tavano L; Muzzalupo R
Colloids Surf B Biointerfaces; 2016 Nov; 147():161-171. PubMed ID: 27500359
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
[TBL] [Abstract][Full Text] [Related]
13. Modification of the C16Y peptide on nanoparticles is an effective approach to target endothelial and cancer cells via the integrin receptor.
Hamano N; Negishi Y; Fujisawa A; Manandhar M; Sato H; Katagiri F; Nomizu M; Aramaki Y
Int J Pharm; 2012 May; 428(1-2):114-7. PubMed ID: 22421321
[TBL] [Abstract][Full Text] [Related]
14. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
Sochanik A; Mitrus I; Smolarczyk R; CichoĊ T; Snietura M; Czaja M; Szala S
Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
[TBL] [Abstract][Full Text] [Related]
15. Stimuli-responsive Smart Liposomes in Cancer Targeting.
Jain A; Jain SK
Curr Drug Targets; 2018 Feb; 19(3):259-270. PubMed ID: 26853324
[TBL] [Abstract][Full Text] [Related]
16. Nutlin-3 loaded nanocarriers: Preparation, characterization and in vitro antineoplastic effect against primary effusion lymphoma.
Belletti D; Tosi G; Riva G; Lagreca I; Galliania M; Luppi M; Vandelli MA; Forni F; Ruozi B
Int J Pharm; 2015 Jul; 490(1-2):85-93. PubMed ID: 25987470
[TBL] [Abstract][Full Text] [Related]
17. Shrapnel nanoparticles loading docetaxel inhibit metastasis and growth of breast cancer.
Xu P; Meng Q; Sun H; Yin Q; Yu H; Zhang Z; Cao M; Zhang Y; Li Y
Biomaterials; 2015 Sep; 64():10-20. PubMed ID: 26106797
[TBL] [Abstract][Full Text] [Related]
18. Designing Liposomes To Suppress Extracellular Matrix Expression To Enhance Drug Penetration and Pancreatic Tumor Therapy.
Ji T; Lang J; Wang J; Cai R; Zhang Y; Qi F; Zhang L; Zhao X; Wu W; Hao J; Qin Z; Zhao Y; Nie G
ACS Nano; 2017 Sep; 11(9):8668-8678. PubMed ID: 28806504
[TBL] [Abstract][Full Text] [Related]
19. A functional nanocarrier that copenetrates extracellular matrix and multiple layers of tumor cells for sequential and deep tumor autophagy inhibitor and chemotherapeutic delivery.
Wang Y; Qiu Y; Yin S; Zhang L; Shi K; Gao H; Zhang Z; He Q
Autophagy; 2017 Feb; 13(2):359-370. PubMed ID: 27911136
[TBL] [Abstract][Full Text] [Related]
20. Drug delivery to solid tumors: the predictive value of the multicellular tumor spheroid model for nanomedicine screening.
Millard M; Yakavets I; Zorin V; Kulmukhamedova A; Marchal S; Bezdetnaya L
Int J Nanomedicine; 2017; 12():7993-8007. PubMed ID: 29184400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
